Axonics, Inc. (NASDAQ:AXNX – Get Free Report) CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Axonics Stock Performance
AXNX opened at $69.63 on Friday. The stock has a fifty day moving average of $68.93 and a 200-day moving average of $68.05. The company has a market capitalization of $3.55 billion, a P/E ratio of -217.59 and a beta of 0.81. Axonics, Inc. has a fifty-two week low of $48.30 and a fifty-two week high of $69.91.
Axonics (NASDAQ:AXNX – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.03. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The business had revenue of $114.57 million during the quarter, compared to analysts’ expectations of $112.83 million. During the same quarter in the previous year, the company earned ($0.15) EPS. The business’s revenue was up 23.3% on a year-over-year basis. On average, equities research analysts predict that Axonics, Inc. will post 0.24 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Axonics
Analysts Set New Price Targets
Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $69.57.
View Our Latest Research Report on AXNX
About Axonics
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
See Also
- Five stocks we like better than Axonics
- Top Biotech Stocks: Exploring Innovation Opportunities
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- 3 Best Fintech Stocks for a Portfolio Boost
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.